bilateral salpingo-oophorectory (BSO)

^[1]^[2]^[3]^[4]

Introduction

bilateral
- ovarian cancer
- fallopian tube cancer
prophylactic bilateral salpingo-oophorectomy (BSO), with or without hysterectomy, after completion of childbearing is the standard of care for female carriers of BRCA1 mutation or BRCA2 mutation^[1]

↑ ^1.0 ^1.1 Rebbeck TR et al. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009 Jan 21; 101:80. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19141781
Greene MH and Mai PL. What have we learned from risk-reducing salpingo-oophorectomy? J Natl Cancer Inst 2009 Jan 21; 101:70. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19141782
↑ Ward SM, Chelmow D Medscape: Salpingo-Oophorectomy http://emedicine.medscape.com/article/1894587-overview
↑ ^3.0 ^3.1 Shu CA et al Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol 2016 Jun 30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27367496 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2531470
Leath CA et al. Drawing the line in risk-reducing gynecologic surgery in women with a BRCA mutation. JAMA Oncol 2016 Jun 30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27367041 <Internet> http://oncology.jamanetwork.com/article.aspx?articleid=2531467
↑ ^4.0 ^4.1 Zeydan B et al. Association of bilateral salpingo-oophorectomy before menopause onset with medial temporal lobe neurodegeneration. JAMA Neurol 2018 Oct 15 https://www.jwatch.org/na47763/2018/10/29/protect-brain-look-ovaries